On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q4 2023 earnings per share (EPS) of $0.11, up 1,200% year over year. Total Biomarin Pharmaceutical earnings for the quarter were $20.38 million. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was -$0.01.
As of Q2 2024, Biomarin Pharmaceutical's earnings has grown 17.11% year over year. This is 35.57 percentage points lower than the US Biotechnology industry earnings growth rate of 52.67%. Biomarin Pharmaceutical's earnings in the past year totalled $167.65 million.
What was BMRN's revenue last quarter?
On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q4 2023 revenue of $646.21 million up 20.22% year over year. In the same quarter last year, Biomarin Pharmaceutical's revenue was $537.54 million.
What was BMRN's revenue growth in the past year?
As of Q2 2024, Biomarin Pharmaceutical's revenue has grown 15.42% year over year. This is 130.31 percentage points lower than the US Biotechnology industry revenue growth rate of 145.73%. Biomarin Pharmaceutical's revenue in the past year totalled $2.42 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.